| Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment M Reda, W Ngamcherdtrakul, MA Nelson, N Siriwon, R Wang, HY Zaidan, ... Nature communications 13 (1), 4261, 2022 | 83 | 2022 |
| Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery W Ngamcherdtrakul, T Sangvanich, M Reda, S Gu, D Bejan, W Yantasee International journal of nanomedicine, 4015-4027, 2018 | 59 | 2018 |
| PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer M Reda, W Ngamcherdtrakul, S Gu, DS Bejan, N Siriwon, JW Gray, ... Cancer letters 467, 9-18, 2019 | 58 | 2019 |
| In situ tumor vaccination with nanoparticle co‐delivering CpG and STAT3 siRNA to effectively induce whole‐body antitumor immune response W Ngamcherdtrakul, M Reda, MA Nelson, R Wang, HY Zaidan, DS Bejan, ... Advanced Materials 33 (31), 2100628, 2021 | 47 | 2021 |
| Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain … W Ngamcherdtrakul, DS Bejan, W Cruz‐Muñoz, M Reda, HY Zaidan, ... Small 18 (11), 2107550, 2022 | 29 | 2022 |
| The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors V Palve, CE Knezevic, DS Bejan, Y Luo, X Li, S Novakova, EA Welsh, ... Cell chemical biology 29 (2), 202-214. e7, 2022 | 25 | 2022 |
| Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling DJ Sanderson, KM Rodriguez, DS Bejan, NE Olafsen, ID Bohn, A Kojic, ... Cell Chemical Biology 30 (1), 43-54. e8, 2023 | 13 | 2023 |
| Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model W Ngamcherdtrakul, J Morry, T Sangvanich, M Reda, DS Bejan, ... Scientific Reports 9 (1), 709, 2019 | 7 | 2019 |
| Structure-guided design and characterization of a clickable, covalent PARP16 inhibitor DS Bejan, S Sundalam, H Jin, RK Morgan, IT Kirby, IR Siordia, B Tivon, ... Chemical Science 13 (46), 13898-13906, 2022 | 5 | 2022 |
| Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors MR Arnold, MF Langelier, J Gartrell, IT Kirby, DJ Sanderson, DS Bejan, ... Cell Chemical Biology 29 (12), 1694-1708. e10, 2022 | 3 | 2022 |
| Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain … W Ngamcherdtrakul, DS Bejan, W Cruz‐Muñoz, M Reda, HY Zaidan, ... Small 18 (11), 2270050, 2022 | 3 | 2022 |
| Methods for profiling the target and off-target landscape of PARP inhibitors DS Bejan, MS Cohen Current Research in Chemical Biology 2, 100027, 2022 | 1 | 2022 |
| β-Chain hydrogen-bonding in 4-hydroxycoumarins TVH Duong, TS Carroll, DS Bejan, EJ Valente Journal of Chemical Crystallography 50, 387-399, 2020 | 1 | 2020 |
| PARP14 is pro-and anti-viral host factor that promotes IFN production and affects the replication of multiple viruses S Parthasarathy, P Saenjamsai, H Hao, A Ferkul, JJ Pfannenstiel, ... bioRxiv, 2024 | | 2024 |
| Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment M Reda, W Ngamcherdtrakul, M Nelson, N Siriwon, R Wang, H Zaidan, ... | | 2022 |
| Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response (Adv. Mater. 31/2021) W Ngamcherdtrakul, M Reda, MA Nelson, R Wang, HY Zaidan, DS Bejan, ... Advanced Materials 33 (31), 2170244, 2021 | | 2021 |
